Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial

Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial

Abstract Introduction Immunoglobulin G4-related disease (IgG4-RD) is a debilitating multiorgan disease characterized by recurring flares leading to organ dysfunction, decreased quality of life, and mortality. Glucocorticoids, the standard of care for IgG4-RD, are associated with substantial treatmen...

Full description

Bibliographic Details
Main Authors: Cory Perugino, Emma L. Culver, Arezou Khosroshahi, Wen Zhang, Emanuel Della-Torre, Kazuichi Okazaki, Yoshiya Tanaka, Matthias Löhr, Nicolas Schleinitz, Judith Falloon, Dewei She, Daniel Cimbora, John H. Stone
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-10-01
Series:Rheumatology and Therapy
Subjects:
Anti-CD19 monoclonal antibody
B-cell depletion
Clinical trial
IgG4-RD
IgG4-related disease
Inebilizumab
Online Access:https://doi.org/10.1007/s40744-023-00593-7

Internet

https://doi.org/10.1007/s40744-023-00593-7

Similar Items